Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.

An 18-year-old is using a high-dose treatment for hair loss, including 2.5 mg dutasteride, topical minoxidil, and injectable GHK-Cu, despite minimal hair loss. Many users suggest reducing the dutasteride dose due to potential side effects and recommend starting with finasteride instead.

A woman with AGA is using spironolactone, dutasteride, finasteride, oral minoxidil, bicalutamide, and anti-androgenic birth control but still experiences worsening hair loss. Steroid shots temporarily stop her hair shedding, leading her to question her biopsy results.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.

The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

A user is seeking advice on mixing GHK-cu/AHK-cu with minoxidil for hair loss treatment. They are asking for recommendations on the correct mixing ratios and any experiences with copper peptides.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

Whey protein may slightly increase hair loss in men with androgenetic alopecia (AGA) due to elevated IGF-1 and testosterone levels, but the effect is minimal compared to treatments like finasteride and dutasteride. Many users argue that whey protein's impact on hair loss is negligible and that maintaining a healthy lifestyle is more important.

A female with male-pattern hair loss (AGA) is seeking help after unsuccessful treatments with spironolactone and supplements, and is considering oral minoxidil and finasteride despite concerns about medication side effects. She has ruled out hormonal birth control and PRP/PRFM, and is looking into further medical advice due to abnormal lab results.

Oral minoxidil treatment increased hair density and shaft caliber in AGA patients. Side effects included hypertrichosis and lower extremity edema, with younger patients experiencing fewer side effects.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.